Screening for chromosomal anomalies in the first trimester: Does repeat maternal serum screening improve detection rates?

Prenatal Diagnosis

Volumn 22, Issue 10, 2002, Pages 903-906

  Spencer, Kevin ^a   Cuckle, Howard S ^b  

^a HAROLD WOOD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Biological variability; Down syndrome; Free hCG; PAPP A; Prenatal screening

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; BLOOD SAMPLING; CHROMOSOME ABERRATION; DOWN SYNDROME; FETUS; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL SERUM; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; SCREENING TEST; TRISOMY 21;

CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CHROMOSOME ABERRATIONS; FALSE POSITIVE REACTIONS; FEMALE; GESTATIONAL AGE; HUMANS; MATERNAL AGE; NECK; PREGNANCY; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0036797852     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/pd.441     Document Type: Article

References (24)

1. Berry E, Aitken DA, Crossley JA, Macri JN, Connor JM. 1997. Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimesters. Br J Obstet Gynaecol 104: 811-817.
2. Cuckle HS, Wald NJ, Nanchahal K, Densem J. 1989. Repeat maternal serum alpha-fetoprotein testing in anteratal screening programmes for Down's Syndrome. Brit J Obstet Gynaecol 96: 52-60.
3. Cuckle HS, van Lith JMM. 1999. Appropriate biochemical parameters in first trimester screening for Down's syndrome. Prenat Diagn 19: 505-512.
4. Cuckle HS, Wald NJ, Thompson SG. 1987. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Brit J Obstet Gynaecol 94: 387-402.
5. Cuckle H, Densem J, Wald N. 1994. Repeat maternal serum testing in multiple maker Down's syndrome screening programmes. Prenat Diagn 14: 603-607.
6. Dar H, Merksamer R, Berdichevesky D, David D. 1996. Matemal serum marker levels in consecutive pregnancies: a possible genetic predisposition to abnormal levels. Am J Med Genet 61: 154-157.
7. Fraser CG, Hyltoft Pedersen P. 1993. Desirable standards for laboratory tests if they are to fulfil medical needs. Clin Chem 39: 1447-1455.
8. Fraser CG, Hyltoft Pedersen P, Libeer J-C, Ricos C. 1997. Proposals for setting generally applicable quality goals solely based on biology. Ann Clin Biochem 34: 8-12.
9. Hackshaw AK, Densem J, Wald NJ. 1995. Repeat maternal serum testing for Down's syndrome screening using multiple markers with special reference to free α and free β-hCG. Prenat Diagn 15: 1125-1130.
10. Holding S, Cuckle H. 1994. Maternal serum screening for Down's syndrome taking account of results of a previous pregnancy. Prenat Diagn 14: 321-322.
11. Larsen SO, Christiansen M, Norgaard-Pedersen B. 1998. Inclusion of serum marker measurements from a previous pregnancy improves Down's syndrome screening performance. Prenat Diagn 18: 706-712.
12. Nicolaides KH, Snijders RJM, Cuckle HS. 1998. Correct estimation of parameters for ultrasound nuchal translucency screening. Prenat Diagn 18: 519-521.
13. Office of Population Censuses and Surveys. 2001. Birth Statistics Series FMI 1996-2000 HMSO: London; 23-27.
14. Royston P, Thompson SG. 1992. Model-based screening by risk with application to Down's syndrome. Stats Med 11: 257-268.
15. Spencer K. 1997a. hCG and its subunits in first trimester Down's syndrome screening. In Screening for Down's Syndrome in the First Trimester, Grudzinskas JG, Ward RHT (eds). RCOG Press: London; 117-131.
16. Spencer K. 1997b. Between pregnancy biological variability of maternal serum alpha fetoprotein and free beta hCG: implications for Down's syndrome screening in subsequent pregnancies. Prenat Diagn 17: 39-45.
17. Spencer K. 2001. Between pregnancy biological variability of first trimester markers of Down's syndrome: implications for screening in subsequent pregnancies. Prenat Diagn 21: 445-447.
18. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 13: 231-237.
19. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. 2000a. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br J Obstet Gynaecol 107: 1271-1275.
20. Spencer K, Tul N, Nicolaides KH. 2000b. Matemal serum free β-hCG and PAPP-A in fetal sex chromosome defects in the first trimester. Prenat Diagn 20: 390-394.
21. Spencer K, Ong C, Skentou H, Liao AW, Nicolaides KH. 2000c. Screening for trisomy 13 by fetal nuchal translucency thickness and maternal serum free β-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 20: 411-416.
22. Spencer K, Liao AWJ, Skentou H, Cicero S, Nicolaides KH. 2000d. Screening for triploidy by fetal nuchal translucency thickness and maternal serum free β-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 20: 495-499.
23. Spencer K, Crossley JA, Aitken DA, Nix ABJ, Dunstan FDJ, Williams K. 2002. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem 39: in press.
24. Tul N, Spencer K, Noble P, Chan C, Nicolaides KH. 1999. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free β-hCG and PAPP-A. Prenat Diagn 19: 1035-1042.